Because tamoxifen was used very widely for early breast cancer in Scotland from the mid-1980s, it was not possible to assemble sufficient unexposed, poor outcome, cases to validate the index based on BCL-2 positivity and presence of carcinoma in situ. Here, BCL2 is linked to breast cancer.